CR20140310A - Agentes de reversión anticoagulante - Google Patents

Agentes de reversión anticoagulante

Info

Publication number
CR20140310A
CR20140310A CR20140310A CR20140310A CR20140310A CR 20140310 A CR20140310 A CR 20140310A CR 20140310 A CR20140310 A CR 20140310A CR 20140310 A CR20140310 A CR 20140310A CR 20140310 A CR20140310 A CR 20140310A
Authority
CR
Costa Rica
Prior art keywords
anticoagulating
reversion agents
reversion
agents
anticoagulating reversion
Prior art date
Application number
CR20140310A
Other languages
English (en)
Spanish (es)
Inventor
Solomon S Steiner
Bryan E Laulicht
Sasha H Bakhru
Edith Mathiowitz
Original Assignee
Perosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Perosphere Inc filed Critical Perosphere Inc
Publication of CR20140310A publication Critical patent/CR20140310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR20140310A 2011-11-29 2014-06-26 Agentes de reversión anticoagulante CR20140310A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US201261666291P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
CR20140310A true CR20140310A (es) 2014-08-20

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140310A CR20140310A (es) 2011-11-29 2014-06-26 Agentes de reversión anticoagulante

Country Status (34)

Country Link
US (5) US9522892B2 (cg-RX-API-DMAC7.html)
EP (1) EP2785700B1 (cg-RX-API-DMAC7.html)
JP (1) JP6134731B2 (cg-RX-API-DMAC7.html)
KR (1) KR101892330B1 (cg-RX-API-DMAC7.html)
CN (1) CN104080772B (cg-RX-API-DMAC7.html)
AP (1) AP2014007662A0 (cg-RX-API-DMAC7.html)
AR (1) AR089020A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012345975B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012892B1 (cg-RX-API-DMAC7.html)
CA (1) CA2856540C (cg-RX-API-DMAC7.html)
CL (1) CL2014001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO6990738A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140310A (cg-RX-API-DMAC7.html)
CY (1) CY1117414T1 (cg-RX-API-DMAC7.html)
DK (1) DK2785700T3 (cg-RX-API-DMAC7.html)
EA (1) EA027603B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14006696A (cg-RX-API-DMAC7.html)
ES (1) ES2569674T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160513T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027452T2 (cg-RX-API-DMAC7.html)
IL (1) IL232788B (cg-RX-API-DMAC7.html)
ME (1) ME02424B (cg-RX-API-DMAC7.html)
MX (1) MX349514B (cg-RX-API-DMAC7.html)
PE (1) PE20141295A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014501176B1 (cg-RX-API-DMAC7.html)
PL (1) PL2785700T3 (cg-RX-API-DMAC7.html)
PT (1) PT2785700E (cg-RX-API-DMAC7.html)
RS (1) RS54738B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201402713WA (cg-RX-API-DMAC7.html)
SI (1) SI2785700T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600161B (cg-RX-API-DMAC7.html)
UA (1) UA116336C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013082210A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404793B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069844A1 (en) * 2013-11-08 2015-05-14 Perosphere Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
PE20200719A1 (es) * 2017-11-13 2020-07-21 Maximum Fidelity Surgical Simulations Llc Reconstitucion de la circulacion posmortem, metodos y procedimientos especializados
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
EP4692086A1 (en) 2023-03-24 2026-02-11 Shaanxi Micot Pharmaceutical Technology Co., Ltd. Anticoagulation reversal agent, and preparation method therefor and use thereof
CN117624137A (zh) * 2023-12-04 2024-03-01 中国药科大学 三嗪骨架小分子肝素逆转剂及其制备方法与用途
US20250389737A1 (en) * 2024-06-20 2025-12-25 Instrumentation Laboratory Company FACTOR Xa REAGENT
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent
CN121622691A (zh) * 2024-08-30 2026-03-10 陕西麦科奥特医药科技股份有限公司 使用抗凝逆转剂治疗抗凝剂导致的出血的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2285454A1 (en) * 1997-04-07 1998-10-15 Axys Pharmaceuticals Corporation Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
JP2002544263A (ja) 1999-05-19 2002-12-24 ファルマシア・コーポレイション 抗凝血剤としての置換多環式アリールおよびヘテロアリールウラシル
CA2412345A1 (en) 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
EP1274676A2 (en) 2000-04-17 2003-01-15 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6586418B2 (en) * 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
BR0213092A (pt) 2001-10-03 2004-10-19 Pharmacia Corp Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação
WO2003082809A1 (en) * 2002-03-27 2003-10-09 Glaxo Group Limited Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
JPWO2003099324A1 (ja) * 2002-05-23 2005-09-22 中外製薬株式会社 組織因子阻害剤中和剤及び活性型血液凝固第vii因子製剤中和剤
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
JPWO2008105441A1 (ja) * 2007-02-27 2010-06-03 味の素株式会社 リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов

Also Published As

Publication number Publication date
UA116336C2 (uk) 2018-03-12
SI2785700T1 (sl) 2016-09-30
CA2856540C (en) 2018-04-03
US20180207152A1 (en) 2018-07-26
CN104080772B (zh) 2016-10-05
US20210169874A1 (en) 2021-06-10
BR112014012892A8 (pt) 2021-06-08
IL232788A0 (en) 2014-08-03
PE20141295A1 (es) 2014-10-01
AR089020A1 (es) 2014-07-23
ME02424B (me) 2016-09-20
CY1117414T1 (el) 2017-04-26
HK1202858A1 (en) 2015-10-09
US20240366592A1 (en) 2024-11-07
HRP20160513T1 (hr) 2016-07-15
EP2785700B1 (en) 2016-03-09
ZA201404793B (en) 2015-04-29
US9522892B2 (en) 2016-12-20
PL2785700T3 (pl) 2016-09-30
SMT201600161B (it) 2016-07-01
CO6990738A2 (es) 2014-07-10
BR112014012892B1 (pt) 2022-12-20
MX349514B (es) 2017-08-02
NZ625337A (en) 2016-11-25
DK2785700T3 (en) 2016-06-13
EA201490823A1 (ru) 2015-01-30
EA027603B1 (ru) 2017-08-31
US20170056396A1 (en) 2017-03-02
CA2856540A1 (en) 2013-06-06
JP2014534270A (ja) 2014-12-18
AU2012345975B2 (en) 2016-12-15
IL232788B (en) 2018-05-31
ECSP14006696A (es) 2015-06-30
ES2569674T3 (es) 2016-05-12
KR20140107259A (ko) 2014-09-04
KR101892330B1 (ko) 2018-08-27
RS54738B1 (sr) 2016-10-31
BR112014012892A2 (pt) 2017-06-13
US20130137702A1 (en) 2013-05-30
JP6134731B2 (ja) 2017-05-24
AP2014007662A0 (en) 2014-05-31
SG11201402713WA (en) 2014-06-27
HUE027452T2 (en) 2016-09-28
AU2012345975A1 (en) 2014-05-29
CL2014001399A1 (es) 2014-11-03
US9877961B2 (en) 2018-01-30
PT2785700E (pt) 2016-06-02
WO2013082210A1 (en) 2013-06-06
PH12014501176A1 (en) 2014-09-01
CN104080772A (zh) 2014-10-01
EP2785700A1 (en) 2014-10-08
PH12014501176B1 (en) 2014-09-01
MX2014006349A (es) 2014-09-04

Similar Documents

Publication Publication Date Title
SMT201500054B (it) 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2787127A4 (en) CONSTRUCTION MACHINE
BR112013030180A2 (pt) peça de roupa de esporte
EP2738397A4 (en) CONSTRUCTION MACHINE
DE102011100082A8 (de) Traygreifvorrichtung
EP2711470A4 (en) WORK MACHINE
EP2720370A4 (en) CONSTRUCTION MACHINE
EP2711468A4 (en) CONSTRUCTION MACHINE
EP2708660A4 (en) CONSTRUCTION MACHINE
EP2687637A4 (en) CONSTRUCTION MACHINE
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
EP2754756A4 (en) CONSTRUCTION MACHINE
EP2791653A4 (en) PROCESS FOR OPTIMIZED SCATTEROMETRY
EP2743407A4 (en) CONSTRUCTION MACHINE
DK3141251T3 (da) Koloskopi - forberedelse
EP2728204A4 (en) CONSTRUCTION MACHINE
EP2743408A4 (en) CONSTRUCTION MACHINE
EP2663189A4 (en) Combination
FI20116167L (fi) Järjestely
BR112014003094A2 (pt) membro de redução de quantidade residual
EP2754757A4 (en) CONSTRUCTION MACHINE
DE112011104936A5 (de) Stanzstauchniet